Morepen Laboratories Ltd

Morepen Laboratories Ltd

Next 500 2024
+ 5 More
+ 5 More
OVERVIEW
FINANCIALS

About

Morepen Laboratories is an Indian pharmaceutical company headquartered in Gurugram and led by Sushil Suri. Among 4 manufacturing facilities, its unit at Baddi houses 10 plants, each tailored to produce a specific product line. Through its brands—Dr. Morepen and Gubb World—Morepen offers over 800 active pharmaceutical ingredients (APIs), formulations, over-the-counter and healthcare products, along with diagnostic services. With regulation certificates from global authorities such as the Food and Drug Administration (FDA) of the US and the World Health Organisation’s good manufacturing practice (GMP), Morepen distributes its products to 82 countries all over the world. Its R&D activities have helped the company gain over 33 patents and file for another 60. Morepen is currently developing more than 25 new molecules to expand its efficacy in the healthcare sector.

Incorporation Year: 1984
Headquarters: Gurugram
Top Management: Sushil Suri
Industry: Pharma

Featured In Fortune India Ranking

Next 500 India
#435(2024)#218(2023)#180(2022)#311(2021)#412(2020)#472(2019)
#435(2024)#218(2023)#180(2022)#311(2021)#412(2020)#472(2019)
Ranking Trend Fortune Next 500 India

Financial Data 2024

Revenue
1,702
(INR Cr)
Net Operating Income
1,690
(INR Cr)
Assets
915
(INR Cr)
Profit
96
(INR Cr)
Net Worth
847
(INR Cr)

Financial Data

RevenueNet Operating IncomeProfitAssetsNet Worth
PARAMETERS2024202320222021202020192018201720162015201420132012201120102009
Revenue
(INR Cr)
1702
21.0%
1407
-10.2%
1567
26.2%
1242
42.3%
873
10.2%
792
30.5%
607
-1.3%
614
25.3%
490
22.2%
401
8.6%
369
12.0%
330
7.4%
307
32.0%
233
-7.3%
251
28.5%
195
-
Net Operating Income
(INR Cr)
1690
19.25%
1418
-8.36%
1547
30.20%
1188
39.27%
853
11.00%
769
26.72%
607
1.85%
595
22.75%
485
21.08%
401
9.21%
367
12.56%
326
12.64%
289
26.74%
228
9.69%
208
14.93%
181
25.21%
Profit
(INR Cr)
96
148.6%
39
-62.0%
102
4.7%
97
189.1%
34
16.4%
29
-2.5%
30
25.2%
24
84.6%
13
498.1%
2
-
-3
-
-21
-
-24
-
-47
-
-6
-
-42
-
Assets
(INR Cr)
915
12.8%
811
29.1%
628
33.5%
471
5.9%
444
9.5%
406
7.7%
377
-1.0%
381
-0.1%
381
0.4%
380
-4.1%
396
-5.7%
420
-6.3%
448
-7.2%
483
-8.9%
530
-7.4%
573
-
Net Worth
(INR Cr)
847
12.5%
753
30.1%
579
36.2%
425
49.5%
284
12.2%
253
12.0%
226
15.1%
196
8.7%
181
7.6%
168
-5.4%
177
-1.5%
180
-10.2%
201
-10.5%
224
-17.3%
271
57.0%
173
-22.0%
Employee Cost
(INR Cr)
181
17.3%
155
-5.8%
164
21.1%
136
23.4%
110
15.3%
95
24.6%
77
9.8%
70
19.6%
58
19.5%
49
8.2%
45
13.6%
40
8.5%
37
18.0%
31
32.0%
24
12.8%
21
-
Interest Cost
(INR Cr)
42-72224811910128643
Cash & Bank Balance
(INR Cr)
5256466839326849965315
Total Debt
(INR Cr)
29251917133132134169688189111121133140280

Key Financial Ratios

Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
PARAMETERS2024202320222021202020192018201720162015201420132012201120102009
Profit As % Of Revenues 5.7%2.8%6.5%7.8%3.9%3.6%4.9%3.9%2.6%0.5%------
Profit As % Of Assets 10.5%4.8%16.2%20.6%7.6%7.1%7.9%6.2%3.4%0.6%------
Profit As % Of Networth 11.4%5.1%17.6%22.9%11.8%11.4%13.1%12.0%7.1%1.3%------
Interest Cost to EBITDA % 2.3%2.5%-1.5%2.9%3.1%6.7%12.3%18.4%18.0%20.3%37.6%41.4%108.7%51.0%246.3%
Debt to Equity Ratio 0.030.030.030.040.470.520.590.860.370.480.500.620.600.590.521.62
RONW 12.1%5.8%20.3%25.9%10.2%8.7%9.0%7.1%5.2%0.8%------
ROCE 16.1%8.0%21.7%20.9%8.5%6.5%6.8%6.0%5.1%2.3%0.0%0.0%0.0%0.0%0.0%0.0%